Blockade of EGFR has been used extensively in the metastatic setting in cases where tumors are proven to be wild type for RAS expression, and although response rates can be higher in some settings with addition of EGFR inhibition, its use in the upfront setting for locally advanced rectal cancers has been shown to cause increased morbidity without clinical benefit.47 The gene discussed is EGFR; the disease is rectal cancer.